NCT05704088View on ClinicalTrials.gov

SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 8, 2022

Primary Completion Date

January 8, 2024

Study Completion Date

January 8, 2024

Conditions
SGLT2 INHIBITORSLupus NephritisBMD
Interventions
DRUG

Dapagliflozin tablet

randomized control trial, study group will receive dapagliflozin tablets

DRUG

placebo

randomized control trial, control group will receive placebo tablets

Trial Locations (1)

35511

Urology and Nephrology Center, Al Mansurah

All Listed Sponsors
lead

Mansoura University

OTHER